A new treatment modality for inoperable or metastasized gastroenteropancreatic tumors is
the use of radiolabeled somatostatin analogs. Initial studies with high doses of [ 111 In-…

Somatostatin receptor imaging (SRI) with [111In-DTPA0] octreotide has proven its role in
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs). …

Many management strategies exist for neuroendocrine liver metastases. These strategies
range from surgery to ablation with various interventional radiology procedures, and include …

Purpose Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs)
are slowgrowing, median overall survival (OS) in patients with liver metastases is 2 to 4 …

Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …

Purpose There are few treatment options for patients with metastasized or inoperable endocrine
gastroenteropancreatic (GEP) tumors. Chemotherapy can be effective, but the response …

Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options. …

The somatostatin analogue [DOTA 0 ,Tyr 3 ]octreotate has a nine-fold higher affinity for the
somatostatin receptor subtype 2 as compared with [DOTA 0 ,Tyr 3 ]octreotide. Also, labelled …

Only advances that occurred from 2011 to 2014 that either strengthen the previous 2011
guidelines [1, 2] or lead to changes or additional guidelines are reviewed here. Advances and …

Gianfranco Delle Fave a Dik J. Kwekkeboom b Erik Van Cutsem c Guido Rindi d Beata Kos-Kudla
e Ulrich Knigge f Hironobu Sasano g Paola Tomassetti h Ramon Salazar i Philippe …